(Q40204869)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

review article

1 reference

title

Antithrombotic assessment and clinical potential of prostacyclin analogues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

author name string

B J Whittle

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

S Moncada

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

language of work or name

1 reference

1 January 1984

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

Progress in medicinal chemistry

11 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

page(s)

237-279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6400136%20AND%20SRC:MED&resulttype=core&format=json

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

11 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Progress in the management of fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostacyclin can replace heparin in haemodialysis in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostacyclin administration during cardiopulmonary bypass in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

A double blind study of prostacyclin in cardiopulmonary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Successful therapy of advanced arteriosclerosis obliterans with prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

EPOPROSTENOL (PROSTACYCLIN) AND SEVERE ARTERIAL DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostacyclin therapy in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Clinical use of prostacyclin (PGI2) in ischaemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The chemical structure of prostaglandin X (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

THE AGGREGATION OF BLOOD PLATELETS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The electronic aggregometer: a novel device for assessing platelet behavior in blood

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Use of the rabbit transverse stomach-strip to identify and assay prostacyclin, PGA2, PGD2 and other prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Early changes in rat brain 5-hydroxytryptamine synthesis after a single electroconvulsive shock

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Comparison of the vasodepressor action of ZK 36 374, a stable prostacyclin derivative, PGI2 and PGE1 with their effect on platelet aggregation and bleeding time in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

A comparative study of PGI2 and two analogues (FCE 21292 and FCE 21258) in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Synthesis of 13,14-dehydroprostacyclin methyl ester: a potent inhibitor of platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Studies of the mechanisms involved in the fate of prostacyclin (PGI2) and 06-keto-PGF1α in the pulmonary circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Inhibition of platelet aggregation and elevation of cyclic-AMP levels in platelets by 13,14-dehydro PGI2 methyl ester

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Effects of 13, 14-dehydroprostacyclin methyl ester on the feline intestinal vascular bed

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Coronary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with prostacyclin and other prostanoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

20-Methylprostacyclin a powerful ‘unnatural’ platelet aggregation inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Some biochemical activities of 10,10-Difluoro-13-dehydroprostacyclin, a chemically stable analog of prostacyclin, in human blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Vasodilation and inhibition of platelet aggregation by prostacyclins with modified ω-side chain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The effect of PGI2 and PGI2 analogues with increased stability on platelet cAMP content and aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Synthesis and characterization of prostacyclin, 6-ketoprostaglandin F1.alpha., prostaglandin I1, and prostaglandin I3

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The relative activity of prostacyclin (PGI2) and a stable analogue 6β-PGI1 on the gastrointestinal and cardiovascular systems

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

On the multiplicity of platelet prostaglandin receptors I. Evaluation of competitive antagonism by aggregometry

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The action of the dihydro derivatives of prostacyclin ?(6R)-PGI1 and (6S)-PGI1 on the heart and the coronary vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Effects of PGI2 and PGI analogues on cAMP levels in cultured endothelial and smooth muscle cells derived from bovine arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

A triple test for screening biological activity of prostacyclin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Circulatory and platelet actions of 6,9-Thiaprostacyclin (PGI2-S) in the cat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Vasodilation produced by prostacyclin (PGI2) and 9(0)-thiaprostacyclin (PGI2-S) in the caninen femoral circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The orally active thia-imino-prostacyclin Hoe 892: antiaggregatory and cardiovascular activities.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Role of renin release in the hemodynamic, renal and dipsogenic actions of the prostacyclin analogue CG 4203 in conscious rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

dl-9a-Deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Anti-platelet aggregating and disaggregating activities of 6,9-methano PGI2

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Gastrointestinal actions of carbacyclin, a stable mimic of prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Platelet and other effects of carboprostacyclin--a stable prostacyclin analogue.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Inhibition of platelet aggregation with intravenous and oral administration of a carboprostacyclin analogue, 15-cyclopentyl-ω-pentanor-5(E)-carbacyclin (ONO 41483) in man

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Metabolism of prostacyclin. Oxidation by rhesus monkey lung 15-hydroxyl prostaglandin dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Recirculation of prostacyclin (PGI2) in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Metabolism of (5E)-6a-carbaprostaglandin I2 by rhesus monkey lung 15-OH prostaglandin dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Selective Binding Site for [3H]Prostacyclin on Platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Prostaglandin I2 receptors in a particulate fraction of platelets of various species

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Identification and characterisation of a prostacyclin- like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, ciloprost, as radioactive ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Evidence for high affinity prostacyclin binding sites in vascular tissue: Radioligand studies with a chemically stable analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Nomenclature for analogs of prostacyclin (PGI2)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

Stereoconfiguration of 5,6-dihydroprostacyclins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970411-9

7 January 2021

10.1016/S0079-6468(08)70411-9

Identifiers

DOI

0 references

1 reference